Apoptosis is a form of programmed cellular death which, unlike necrosis, does not involve the release of harmful substances into the extra-cellular environment. Three main pathways are involved in apoptotic signalling: the extrinsic pathway, the intrinsic pathway, and the perforin/granzyme. Each pathway leads to the activation of the so termed “execution pathway”; beginning with caspase-3 activation, and involving various mechanisms of cellular death (e.g. chromosomal degradation, cytoskeletal degradation, phagocytic uptake of apoptotic bodies) (reviewed in [1] ). Consequently, the quantification of activated capase-3 is a common marker for determining apoptotic cell death (reviewed in [2] [3] ).

High levels of apoptosis occur during development as a consequence of an initial overproduction of neurons. Estimates are that up to half of the original neuronal population is later pruned through apoptosis [4] [5] . Neurons receiving adequate stimulation through trophic support from glial cells, presynaptic cells, and steroid hormones are retained, while neurons not receiving proper stimulation are pruned [6] - [8] . This process is tightly regulated, as excessive levels can result in over-pruning of synaptic connections while insufficient levels can result in under-pruning of synaptic connections, with either scenario being sub-optimal for and detrimental to normal CNS maturation.

Although appropriate cell death via apoptosis is normal and necessary, these same apoptotic processes can be inappropriately commandeered, and are indeed implicated in cellular death which is innate to various neuropathological states/neurodegenerative disorders [9] - [11] . Inappropriate cell death also appears to be part of the underlying pathophysiology of schizophrenia (as reviewed in [12] ), with reduced neuropil [13] [14] , reductions in presynaptic markers such as synaptophysin and synaptosomal-associated protein 25 [15] , increased prefrontal neuronal apoptosis inhibitor protein [16] , abnormalities in prefrontal synaptic proteins such as N-ethylmaleimide sensitive factor fusion protein and synapsin II [17] and decreased prefrontal dendritic spine density [13] being reported in the cortex of those with schizophrenia. Additionally, others report decreased prefrontal white mater [18] layer-specific reductions in interneurons in layer II of prefrontal cortex and in layers IIBVI of the anterior cingulate cortex [19] and pyramidal neurons in layer IV of anterior cingulate cortex [20] , reductions in neuronal number in the nucleus accumbens (NAcc) [21] and mediodorsal thalamus [22] , and reductions in oligodendrocytes and glial cells in general in the PFC [23] [24] in those with schizophrenia. Collectively these data suggest that either increased cellular apoptosis or increased synaptic apoptosis, the latter referring to a form of apoptosis that targets synapses and/or distal neurites without affecting the remaining portion of a neuron [25] , occurs in individuals with schizophrenia.

Although the literature clearly suggests that changes in apoptosis occur as part of the pathogenesis of schizophrenia, paradoxically, not all findings report an increase in apoptotic processes. In fact, in a review by Jarskog (2006) [26] , he summarizes a number of studies that report a decrease in apoptotic markers in schizophrenia, particularly in cases of chronic schizophrenia. He speculates that this can reflect some one, or combination of, factors that result from an inappropriate response to an apoptotic insult or may reflect some compensatory response to earlier apoptotic processes.

In summary, alterations in programmed cell death consistently occur as a correlate in schizophrenia. Whether apoptosis is up-regulated or down-regulated may depend on the timing of the analysis or on the chronicity of the disorder, but clearly alterations in apoptosis reflect alterations in neuronal survival/circuitry that likely play a significant role in the behavioral manifestations of the disorder.

We have previously reported that, as adults, rats that were chronically exposed to very low doses of DOM during critical periods of CNS maturation, demonstrate persistent behavioural abnormalities that are consistent with those observed within the clinical population and that are homologous with those reported in other animal models of this disorder (reviewed in [27] ). These behavioural abnormalities include deficits in PPI [28] and LI [29] memory dysfunction [30] [31] and social withdrawal [32] . Therefore, the current study was conducted in order to determine whether early exposure to domoate would alter apoptotic processes in the medial prefrontal cortext (mPFC) in pre-weanling rats, thus altering the normal course of CNS maturation.

Results revealed statistically significant treatment effects with DOM-treated males demonstrating decreased optical density measurements in the right PrL [t(8) = −2.838, p = 0.022] (Figure 1 and Figure 2) and with DOM- treated females demonstrating decreased immunopositive cell counts in the right PrL [t(8) = −2.307, p = 0.050] (Figure 3).

In addition to these statistically significant findings, a consistent tendency for decreased caspase-3 staining noted in DOM-treated rats compared to their saline counterparts. This pattern held true for all data―whether quantified using cell counting techniques, or when assessed using optical density methods―a pattern which was notable bilaterally and for both male and female rats (Table 1).

Data from the current study indicate that neonatal treatment with DOM from PND 8 - 14 (i.e. a critical period of brain development which is approximately equivalent to the third trimester of human development) [36] , resulted in decreased caspase-3 staining in the right PrL in both DOM-treated male (as demonstrated by optical density measurements) and female (as demonstrated by cell count measurements) juvenile rats.

We believe that these findings, while modest, could serve as an important first step in mechanistically linking our earlier reported behavioral abnormalities to their more proximal cause. Our previous reports which have shown altered PPI [28] , abnormal LI [29] , social withdrawal [32] , changes in emotionality [37] , altered responses to novelty and drug reinforcement [38] and deficits in learning and memory [30] [31] [39] following this early toxin-treatment regime could indeed be consequent to altered apoptotic processes. For instance, decreases in caspase-3 immunoreactivity could reflect lower levels of apoptosis during the time period assessed (i.e. 1 week following toxin treatment). It may be that low doses of DOM provide survival signals via glutamate receptor activation [40] . However, it is also possible that the opposite is true; that our results indicate an earlier-than-normal period of increased cell death (i.e. during the treatment regime), perhaps as a result of glutamate hyperactivity/excitotoxicity [41] [42] . Either scenario would most likely alter PFC circuitry and, in turn, could result in the behavioural anomalies we have reported on previously.

Although much remains to be discerned with respect to the proximal cause(s) and more distal consequence(s) of the results reported herein, we have demonstrated alterations tocaspase-3 expression in the PrL of pre- weanling rats. As such, these data suggest that as a consequence of this early low-dose toxin treatment, the establishment of appropriate prefrontal connections (e.g. synaptic structure and function) may be persistently altered.

Etiological validity involves recapitulating the clinical etiology of the disorder in question [43] . It is our contention that, in addition to face validity (e.g. symptom similarities), our treatment regime of neonatal chronic low-dose DOM-exposure has inherent etiological validity as an animal model of schizophrenia due to its neurodevelopmental nature. Moreover, we believe that this validity is further strengthened by the results reported herein.

In summary, altered caspase-3 in the PrL suggests that early domoate-treatment may result in persistent abnormalities in synaptic structure and function, a finding that is relevant in terms of improving the etiological validity of our early domoate-treatment regime as a neurodevelopmental model which may have application in schizophrenia research. These findings provide a contextual frame-work for understanding the cognitive abnormalities that are reliably observed in adult animals that are treated neonatally with very low doses of domoic acid during critical periods of CNS maturation.

Funding for this study was provided by a grant from the Natural Science and Engineering Research Council of Canada (NSERC) awarded to TA Doucette. MAR was supported by NSERC and Hooper/Klarenbach Research Post-Graduate Scholarships.

Mark A. Robbins,Catherine L. Ryan,Tracy A. Doucette, (2016) Alterations in Caspase-3 in Juvenile Rats Treated Neonatally with Domoic Acid. Journal of Behavioral and Brain Science,06,357-363. doi: 10.4236/jbbs.2016.69034